BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//PlainTrial//Saved Trials Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:PlainTrial saved trials
X-WR-CALDESC:Estimated completion dates for the clinical trials you saved o
 n PlainTrial.
BEGIN:VEVENT
UID:plaintrial-NCT06170788-completion@plaintrial.com
DTSTAMP:20261027T122832Z
DTSTART;VALUE=DATE:20300527
SUMMARY:Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab
  Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCL
 C) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS
 ) ≥ 50% (MK-2870-007) — estimated completion date
DESCRIPTION:Recruiting. Saved on your PlainTrial shortlist. Full trial reco
 rd: https://plaintrial.com/trial/NCT06170788
URL:https://plaintrial.com/trial/NCT06170788
END:VEVENT
END:VCALENDAR